O steoarthritis (OA) is a multifactorial disease characterized by inflammation and joint degeneration that results in the progressive loss of cartilage and usually is accompanied by subchondral bone sclerosis and, in many cases, formation of bone cysts and marginal osteophytes. 1 Besides these intrinsic disorders of the joints, other signs such as decreased range of motion, pain and joint effusion, crepitation, deformities, and functional loss often are present. 2 Osteoarthritis is one of the most prevalent diseases in the world and is commonly present in the knee joint. It is the major cause of physical limitation and reduction in quality of life. 1, 2 Osteoarthritis affects more than 60% of the population over 40 years of age, and the commitment level varies according to age, especially in women. 3 The exact etiology of OA remains unclear, but the disease is frequently associated with metabolic or endocrinological factors, heredity, obesity and joint overload, and repetitive microtraumas. 4, 5 Because the major complaints of patients with OA are joint pain, stiffness, and functional deficits, 5 the main treatment recommendations have focused on symptom relief and improvement of functional status. 4, 6 Many interventions have been used for lifestyle modification, including weight reduction, drugs, surgery, and specific physical therapy interventions such as exercises and physical agents. 7-10 Among these agents, we are concerned with the electromagnetic radiation applied by a shortwave device in either continuous or pulsed form. [11] [12] [13] Some authors have used pulsed shortwave (PSW) therapy with the goal of minimizing thermal effects generated by conventional, continuous applications, while emphasizing the effects of incremental cellular trophism and metabolism. 11, 14, 15 Other authors have hypothesized that the effects of PSW treatment probably are related to increased local cellular activity and that PSW treatment reduces edema and the inflammatory process, increases the rate of fibrin and collagen deposits, and aids in tissue regeneration without interfering with the nervous system or the hypothalamus. 16 -18 However, the effectiveness of the PSW treatment in people with knee OA remains controversial. Results of some clinical trials have shown positive effects, 10, 11, 19 whereas the results of other clinical trials have not shown positive effects. 20 -22 These conflicting results seem to be related to the great variation of applied energy and treatment duration, which ranged between 2 and 180 kJ and 15 to 40 minutes, respectively. For this reason, controlled trials with different doses are needed to evaluate the effectiveness of the PSW application in the management of knee OA.
Therefore, this study aimed to evaluate the short-term and long-term effects of PSW treatment and to compare this treatment with control and placebo interventions, as well as to evaluate probable differences in low or high doses of PSW.
Method Participants

This
prospective, randomized, placebo-controlled, multicenter study was performed in the physical therapy sectors of the Irmandade da Santa Casa de Misericórdia de São Paulo (ISCMSP)
The Bottom Line
What do we already know about this topic?
Electrothermotherapy devices have been used to treat patients with knee osteoarthritis in order to reduce pain and improve function. However, the effectiveness of these devices, especially pulsed shortwave, is still controversial.
What new information does this study offer?
According to this study, the application of pulsed shortwave is an effective method for reducing pain and improving function in women with knee osteoarthritis. High or low doses of pulsed shortwave treatment are more effective than placebo treatment or no treatment.
If you're a patient, what might these findings mean for you?
If you have knee osteoarthritis, adding pulsed shortwave treatment to your therapeutic exercise program may increase the benefits of therapy. More research is needed, however, to determine the duration of this improvement. The patients were included in the study if they were over 40 years of age, had primary grade II or III knee OA based on Gupta and colleagues' radiographic criteria, 2 and had had joint or anterior knee pain for at least 3 months. We excluded patients with a history of surgery or any invasive procedure of the affected knee, physical therapy for knee injuries or any medication that had changed in the last 3 months, or other diseases affecting function and patients who presented any contraindication for application of PSW treatment, especially metallic implants, pacemakers, lack of sensitivity, or tumor. 20 All volunteers were informed about the procedures for the study and signed informed consent agreements written in accordance with the National Health Council, resolution 196/96. Inclusion criteria were established previously, and the patient's selection was performed by a physical therapist (T.Y.F.) with 8 years of experience in knee rehabilitation. This examiner was responsible for the pretreatment and posttreatment evaluations, as well as the 12-month follow-up (Figure) . The examiner was blinded to the group assignments and did not participate in the intervention.
Available
The assignment of participants to 4 groups was performed randomly using opaque and sealed envelopes containing the names of the groups: control, placebo, low-dose PSW, and high-dose PSW. The envelopes were picked by an individual not involved in this study. Group assignment was performed following the initial evaluation and just minutes prior to the initial treatment session. Two therapists in each center were trained in the application protocol for the study and provided all treatment.
Interventions
The treatment was performed with 2 previously calibrated Diatermed II devices* with a carrying frequency of 27.12 MHz, a peak power of 250 W, and a pulse duration of 400 microseconds. These parameters are predetermined in the device according to the manufacturer. We used the maximum power provided by the machine in a pulsed form with a pulse frequency of 145 Hz, resulting in a mean power of 14.5 W. These settings were based on the fact that applications with a mean power below 20 W minimize the thermal effects. 11, 18 To calculate the mean power, the following formula was used:
Mean power ͑W͒ ϭ peak power ͑W͒ ϫ pulse duration ͑s͒ ϫ pulse frequency ͑Hz͒
In the low-dose PSW group, the treatment had a duration of 19 minutes per session, with approximately 17 kJ of total energy. The high-dose PSW group received 38 minutes of treatment, with 33 kJ of total energy. 11,18 To calculate these energy values, the following equation was used:
Both groups were given 3 applications of PSW treatment per week, totaling 9 sessions. The PSW treatment was administered using a standard size malleable electrode applied on the anterior area of the thigh, 5 cm above the superior border of the patella, and a second electrode applied on the posterior area of the leg, with the participant positioned supine. The knee was kept in semiflexion at 20 degrees.
The control group did not receive any form of treatment, and all participants in this group were instructed to maintain their daily activities. A placebo group also was established, for which the PSW device was turned on but kept in standby mode during 19 minutes without any electrical current being applied. The participants in the placebo group also received 9 sessions of treatment. The control and placebo groups were used for comparison of the results of the low-dose and high-dose PSW groups. It is important to highlight that the therapists did not remain beside the participants during treatment to avoid * Carci, R. Dr. Siqueira Campos, 246 Liberdade, São Paulo, Brazil.
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influencing the results. No advice was given to participants in both centers in relation to physical activities, except to maintain their daily activities and to avoid using antiinflammatory drugs. Participants in the placebo and treatment groups remained blinded during the 12-month follow-up.
Evaluation
The participants were evaluated in 3 phases: at the initial evaluation (pretreatment), immediately after treatment, and at a 12-month follow-up. An 11-point numerical pain rating scale (NPRS) was used to measure pain during the last 2 days of treatment, where 0 corresponded to "no pain" and 10 corresponded to "worst imaginable pain." The NPRS has been shown to yield reliable and valid scores, with an MCID of 2 points. 25, 26 We administered a validated KOOS questionnaire as a functional measure. 27, 28 The KOOS questionnaire is designed specifically for patients with knee injuries and OA. It consists of 5 subscales: symptoms, daily activities, pain, recreational function, and quality of life. The answers are based on reports from the previous week, where a score of 0 corresponds to "functional impairment" with exacerbated symptoms and a score of 100 corresponds to "normal function" without symptoms. Each subscale was normalized and analyzed individually. The MCID of the KOOS is not yet well defined, but may vary between 10% and 40% depending on the initial result. 23, 24 We did not perform a 12-month follow-up of the control group because after the first arm of the study, the participants in 
Pulsed Shortwave Treatment in Women With Knee Osteoarthritis
that group were referred for traditional physical therapy.
Data Analysis
Data were analyzed with SPSS, version 13.0. † Descriptive statistics for demographic data and all outcome measures were expressed as means and standard deviations. Comparisons among groups were performed, using one-way analyses of variance (ANOVAs), for age, body mass, height, and body mass index to show homogeneity of the sample at baseline. The data for the KOOS and the NPRS were analyzed using a mixed model (group ϫ time) ANOVA. The factor "group" had 4 levels (control, placebo, low-dose PSW, and high-dose PSW), and the repeated factor "time" had 3 levels (preintervention, postintervention, and 12-month follow-up, except for the control group). We also compared the proportion of participants who met or exceeded the MCID in the posttreatment evaluation compared with baseline for the pain and functional scales in the studied groups.
Results
Baseline and Demographic Data
There were no statistically significant differences (PϾ.05) for age, height, body mass, and body mass index among the 4 groups (Tab. 1). There also were no statistically significant differences (PϾ.05) among groups for any of the outcome variables at baseline (preintervention) (Tab. 2). Knee pain for at least 3 months was used as an inclusion criterion; however, all participants had had pain for more than 6 months.
Pain and Function
The group ϫ time interaction for the mixed-model ANOVA (pretreatment ϫ posttreatment) was statistically significant (PϽ.05) for the The posttreatment analysis showed that both low-dose PSW and highdose PSW groups were statistically different compared with the control and placebo groups for the KOOS symptoms and daily activities subscales (rangeϭPϽ.05-PϽ.001). There was no difference between the treatment groups (PϾ.05). For the KOOS pain and quality of life subscale analyses, the low-dose PSW and high-dose PSW groups were statistically different only when compared with the control group (rangeϭPϽ.05-PϽ.001). We did not find any difference for the KOOS recreational activities subscale (PϾ.05). In the NPRS analysis, only the lowdose PSW group showed decreases in pain compared with the control and placebo groups (PϽ.05 and PϽ.01), respectively. There was no difference between the placebo and control groups for any of the scales (PϾ.05).
The group ϫ time interaction between the pretreatment evaluation and the 12-month follow-up was significant only for the KOOS symptoms, pain, and daily activities subscales (PϽ.05). Planned pair-wise comparisons indicated that both low-dose PSW and high-dose PSW groups maintained improvement on the KOOS pain subscale ( 
Intention-to-Treat Analysis
The dropout of 9 participants in the first part of the study did not affect the potential validity of the study (effect size of interest), because in terms of intention to treat (ITT), these dropouts did not exceed 10% of the total. 29,30 However, there was a dropout of 29 participants (approximately 30%) in the second part of the study, which showed a clear necessity to conduct an ITT analysis. As shown in the Figure, 7 participants in the placebo group were lost to 12-month follow-up: 3 did not attend the invitation after 2 telephone calls (lost to evaluation), 3 performed other therapies such as acupuncture and traditional physical therapy in other services, and 1 had a total knee replacement (TKR). Eleven participants in the low-dose PSW group were lost to 12-month follow-up: 5 were lost to evaluation, 5 performed other therapies such as physical therapy and acupuncture, and 1 had a TKR. Finally, 11 participants in the high-dose PSW group were lost to 12-month followup: 5 were lost to evaluation, 4 performed other therapies such as physical therapy and infiltration, and 2 had a TKR. Thus, we performed an ITT analysis using the last observation carried forward, and the results were consistent with the per-protocol analysis, as previously presented.
MCID Analysis
Based on the MCID for the NPRS (2 points), the proportion of patients who met or exceeded the MCID in High-dose PSW 6.7Ϯ2.5 (0.9) 4.6Ϯ2.5 (0.9) 5.2Ϯ2.1 (0.8)
a All values are presented as meanϮSD (95% confidence interval). KOOSϭKnee Injury and Osteoarthritis Outcome Score; a higher score on the KOOS represents better function. NPRSϭ11-point numerical pain rating scale (0 -10 cm), where 0 means "no pain" and 10 means "worst imaginable pain."
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the posttreatment evaluation compared with baseline was 15% in the control group, 15% in the placebo group, 75% in the low-dose PSW group, and 50% in the high-dose PSW group, and the difference between the treatment groups and the control and placebo groups was significant (PϽ.05). Unfortunately, we did not find an MCID standard value for the KOOS questionnaire, but there is speculation that improvement can be significant when the proportion of patients who meet or exceed the MCID is above 10% to 40%. Thus, when we examined the first part of the study, the proportion of patients who met or exceeded 40% of improvement was 15% in the control group, 15% to 25% in the placebo group, 55% to 65% in the low-dose PSW group, and 35% to 50% in the high-dose PSW group.
In the second part of the study, we conducted a 12-month follow-up to assess the long-term effects of PSW application in patients who received some intervention. We observed in the per-protocol analysis and confirmed in the ITT analysis that lowdose PSW treatment maintained the therapeutic effect for the KOOS symptoms, quality of life, and pain subscale (ie, the proportion of patients who met or exceeded the MCID ranged around 40%). The highdose PSW group maintained the results only for KOOS pain subscale (MCID of 50%).
Discussion
The results of this study demonstrate the short-term effectiveness of PSW treatment at low or high doses in patients with knee OA. Both treatment groups showed significant reduction in pain and improvement in function compared with the control and placebo groups. However, recent studies have been concerned with analyzing these results regarding the clinical meaningfulness of the observed effect sizes. 24, 26, 31 By itself, a per-protocol analysis of the raw data has not been accepted as the only way to compare groups. An MCID analysis also is required to obtain parameters and significance of scales, 29 and for this reason it was used in the present study (see the "MCID Analysis" section). Two impor- In the present study, we showed the effectiveness of PSW treatment with either a low dose (power of 14.5 W, treatment duration of 19 minutes, and total energy of 17 kJ) or a high dose (power of 14.5 W, treatment duration of 38 minutes, and total energy of 33 kJ). These results were maintained over the long term, especially for the low doses, despite the obvious high dropout rate.
Although it was not the aim of the study, we believe that the reduction in pain, increased joint lubrication and tissue relaxation, and improvement in function may have stimulated a better movement and gait pattern, as well as increased physical activity over time. However, no advice or orientation was given to patients in relation to physical or sports activities, except to maintain their daily activities and to avoid using anti-inflammatory drugs.
Finally, in addition to the beneficial effects of the PSW treatment for patients with knee OA, it was noted that a prolonged application time is not necessary because a total time of 20 minutes can reach the therapeutic window proposed in the literature. It is noteworthy that these results were achieved without physical exercise, which could have positively influenced the results. Thus, PSW therapy can be an important tool associated with kinesiotherapy in the rehabilitation program.
Conclusion
Pulsed shortwave treatment is an effective method for providing pain relief and improvement in function and quality of life in the short term for women with knee OA. Treatments with low or high doses are more effective than placebo treatment or no treatment. There were no differences between PSW treatment doses, despite the fact that lowdose PSW treatment appears to be more effective in the long term. However, conclusions regarding the long-term effects need to be carefully considered due to the excessive dropout rate during the 12-month follow-up. On the basis of our results, we recommend PSW application in the female population with knee OA. 
